Effects on bone mineral density of a monophasic combined oral contraceptive containing nomegestrol acetate/17β‐estradiol in comparison to levonorgestrel/ethinylestradiol
- 21 August 2012
- journal article
- research article
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 91 (11), 1279-1285
- https://doi.org/10.1111/j.1600-0412.2012.01498.x
Abstract
To compare the effects of a monophasic combined oral contraceptive containing nomegestrol acetate/17β-estradiol (NOMAC/E2) on bone mineral density with a combined oral contraceptive containing levonorgestrel/ethinylestradiol (LNG/EE). Prospective, randomized, open-label, comparative clinical study. Gynecology center in Norway. One hundred and ten women (20-35 years old) actively seeking contraception. Methods. For 26 consecutive 28-day cycles, women received one of the following two treatments: NOMAC/E2 (2.5 mg/1.5 mg) in a 24/4-day regimen (n= 56); or LNG/EE (150 μg/30 μg) in a 21/7-day regimen (n= 54). Main outcome measures. Bone mineral density of the lumbar spine, femoral neck, hip and trochanter (measured by dual energy X-ray absorptiometry); associated z-scores of the lumbar spine and femoral neck. In NOMAC/E2 users, mean (±SD) z-score change from baseline for lumbar spine and femoral neck were 0.019 ± 0.242 and -0.007 ± 0.228, respectively, vs. 0.121 ± 0.269 and 0.044 ± 0.253 in LNG/EE users, respectively. Differences between treatment groups were not significant (p= 0.19 and p= 0.57, respectively). There were no significant differences between changes in hip and trochanter z-scores between NOMAC/E2 and LNG/EE treatments. After two years, NOMAC/E2 had no clinically relevant effect on bone mineral density. No significant difference in the effect on bone mineral density between NOMAC/E2 and LNG/EE was observed.Keywords
This publication has 34 references indexed in Scilit:
- Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolismThe European Journal of Contraception & Reproductive Health Care, 2011
- Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimenThe European Journal of Contraception & Reproductive Health Care, 2011
- Oral Contraceptive Use and Bone Density Change in Adolescent and Young Adult Women: A Prospective Study of Age, Hormone Dose, and DiscontinuationJournal of Clinical Endocrinology & Metabolism, 2011
- Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiolThe European Journal of Contraception & Reproductive Health Care, 2010
- Oral contraceptive use and bone density in adolescent and young adult womenContraception, 2009
- Nomegestrol acetate may enhance the skeletal effects of estradiol on biochemical markers of bone turnover in menopausal women after a 12-week treatment periodClimacteric, 2005
- Overview of the relationship between use of progestogen-only contraceptives and bone mineral densityBritish Journal of Obstetrics and Gynaecology, 2001
- Overview of the relationship between use of progestogen‐only contraceptives and bone mineral densityBJOG: An International Journal of Obstetrics and Gynaecology, 2001
- A prospective, controlled study of the effects of hormonal contraception on bone mineral densityObstetrics & Gynecology, 2001
- Oral contraceptive use may protect against low bone mass. Henry Ford Hospital Osteoporosis Cooperative Research GroupArchives of Internal Medicine, 1991